Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.
Employees: 201-500
Founded date: 2003
Investors 2
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| - | Rho Ventur... | rhoventure... |
Mentions in press and media 20
| Date | Title | Description |
| 24.10.2025 | Cramer’s Lighting Round: Apollo Global Management is a buy | Monday - Friday, 6:00 - 7:00 PM ET It’s that time again! “Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed. Apollo Global Management: ”[buy, buy, buy!]... |
| 05.08.2024 | Vanda Pharmaceuticals: Navigating Challenges and Opportunities in the Biopharmaceutical Landscape | Vanda Pharmaceuticals is at a crossroads. The company recently reported its second-quarter financial results for 2024, revealing a mix of growth and challenges. With revenues of $50.5 million, Vanda saw a 6% increase from the previous quart... |
| 31.07.2024 | Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results | Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; comme... |
| 01.07.2024 | Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex | WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings th... |
| 13.06.2024 | Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak | No Shareholder Action Required at This Time WASHINGTON, June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited propos... |
| 24.05.2024 | Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders | WASHINGTON, May 24, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LL... |
| 15.05.2024 | Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness | • New Drug Application expected to be submitted in Q4 2024 WASHINGTON, May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickn... |
| 08.05.2024 | Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results | Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch expected in Q3 2024 ... |
| 27.02.2023 | Money Moves: Sublime raises $9.8M to build out email security platform | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at dc@technical.ly. With a $9.8 million round, DC-based email tech startup Sublime is moving out of stealth The startup has ... |
| 09.11.2022 | Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences | WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) VNDA today announced that the company will participate in the following upcoming investor conferences in November 2022: The Stifel 2022 Healthcare Conference on Tue... |
Show more